Please login to the form below
Imfinzi
This page shows the latest Imfinzi news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s Imfinzi shown to improve survival chances in lung cancer patients
The AEGEAN results provide compelling evidence that this novel [Imfinzi] regimen can drive improved outcomes in this curative-intent setting.”. ... We have shown that adding Imfinzi both before and after surgery significantly increased the time
Latest news
-
European Commission grants AstraZeneca three new approvals
The European Commission (EC) has granted AstraZeneca three new drug approvals, with the company’s Imfinzi/Imjudo immunotherapy combinations authorised for advanced liver and lung cancers, and a tablet formulation of ... These approvals for Imfinzi and
-
AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
AstraZeneca's (AZ) Imfinzi (durvalumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat biliary tract cancer (BTC) in combination with chemotherapy, the company announced. ... AstraZeneca’s application for
-
AstraZeneca to acquire Neogene Therapeutics in $320m deal
This month, it received recommendations for Imfinzi (durvalumab), Enhertu (trastuzumab deruxtecan) and Lynparza (trastuzumab deruxtecan) from the European Medicines Agency’s Committee for Medicinal Products for Human use for the treatment
-
AstraZeneca receives CHMP recommendations for Imfinzi, Enhertu and Lynparza
AstraZeneca (AZ) has received recommendations for Imfinzi, Enhertu and Lynparza from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) for the treatment of biliary tract ... Imfinzi (durvalumab) has been
-
AstraZeneca’s Imjudo/Imfinzi combination approved by FDA for unresectable liver cancer
AstraZeneca’s Imjudo (tremelimumab) – an anti-CTLA4 antibody – in combination with Imfinzi (durvalumab) – an anti-PD-L1 antibody – has been approved by the US Food and Drug Administration (FDA) for the ... The dosing schedule of the combination
More from news
Approximately 38 fully matching, plus 89 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
Cancer therapies Tagrisso (osimertinib) – now AZ’s top-selling drug – Lynparza (olaparib) and Imfinzi (durvalumab) are already gathering momentum, as they rack up additional indications that extend their use and there ... checkpoint inhibitor
-
Leading AstraZeneca’s return to growth in Europe
Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase.
-
Immuno-oncology in 2019: the rapid evolution continues
In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and
-
AstraZeneca’s oncology renaissance
EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way ... Of course, AstraZeneca isn’t immune to the setbacks of old –
-
AstraZeneca: building a new ‘open innovation’ pharma company
Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –
More from intelligence
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
